Journal for Immunotherapy of Cancer
-
Publication Venue For
- HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression.. 8. 2020
- MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy.. 8. 2020
- First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.. 8. 2020
- Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.. 8. 2020
- Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.. 8. 2020
- Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.. 8. 2020
- The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).. 7:354. 2019
- Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?. 7:325. 2019
- Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.. 7:272. 2019
- Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.. 7:265. 2019
- Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.. 7:218. 2019
- Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.. 7:142. 2019
- Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.. 7:104. 2019
- Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.. 7:84. 2019
- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.. 7:80. 2019
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.. 7:27. 2019
- Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.. 7:18. 2019
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.. 6:111. 2018
- White paper on microbial anti-cancer therapy and prevention.. 6:78. 2018
- Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.. 6:77. 2018
- Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.. 6:54. 2018
- Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.. 6:51. 2018
- Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.. 6:9. 2018
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.. 6:4. 2018
- Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.. 5:102. 2017
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.. 5:44. 2017
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.. 4:52. 2016
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.. 4:89. 2016
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.. 4:15. 2016
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.. 4:44. 2016
- Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.. 4:34. 2016
- Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.. 3:13. 2015
- Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.. 3:6. 2015
- Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.. 3:50. 2015
- Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients.. 3:P444-P444. 2015
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.. 3:19. 2015
- Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771.. 3:P357-P357. 2015
- Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.. 2:20. 2014
- Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.. 1:21. 2013
- Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.. 1:P129-P129. 2013
- A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021 2019
- A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab 2019
- A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy 2019
- Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC) 2019
- Utilization of second-line immuno-oncology agents and associated health outcomes among united states veterans with advanced non-small cell lung cancer 2019
- A HSP-TLR-Wnt5a paracrine signaling axis drives CXCR2 ligand recruitment of myeloid-derived suppressor cells and represents a novel adaptive resistance mechanism to anti-PD-1 antibody therapy 2017
- Chemotherapy enhances oncolytic recombinant poliovirus efficacy 2017
- Generation of therapeutic RNAs to induce immunogenic cell death and interferon expression in cancer cells 2017
- Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab +/- ipilimumab: CheckMate 142 2017
- PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus 2017
- Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy
- The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.